Senju Pharmaceutical has been granted a patent for a medicament that treats or prevents diseases associated with abnormal extracellular matrix in the corneal endothelium. The medicament contains a TGF-beta signal inhibiting agent and is specifically effective in treating Fuchs’ endothelial corneal dystrophy and its related conditions. GlobalData’s report on Senju Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Senju Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Senju Pharmaceutical's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Medicament for treating fuchs' endothelial corneal dystrophy using tgf-beta signal inhibiting agent
A recently granted patent (Publication Number: US11730722B2) discloses a method for treating Fuchs' endothelial corneal dystrophy or related diseases, disorders, or conditions. The method involves administering a medicament containing a transforming growth factor-beta (TGF-beta) signal inhibiting agent to the subject. The TGF-beta signal inhibiting agent alone is effective in treating Fuchs' endothelial corneal dystrophy or its related conditions.
Fuchs' endothelial corneal dystrophy is a progressive eye disease that affects the cornea, leading to vision impairment and discomfort. The patented method aims to address this condition by inhibiting the TGF-beta signaling pathway, which plays a role in the development and progression of Fuchs' endothelial corneal dystrophy.
The method described in the patent involves administering a medicament containing an effective amount of a TGF-beta signal inhibiting agent to the subject. The TGF-beta signal inhibiting agent can be one or more specific compounds, including 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide, bone morphogenic protein (BMP)-7, anti-TGF-beta antibody, anti-TGF-beta receptor antibody, siRNA of TGF-beta, siRNA of a TGF-beta receptor, shRNA of TGF-beta, shRNA of a TGF-beta receptor, an aptamer of TGF-beta, an aptamer of a TGF-beta receptor, an antisense oligonucleotide of TGF-beta, and various other compounds.
The method can be applied to treat not only Fuchs' endothelial corneal dystrophy but also other disorders related to this condition. It is particularly effective in cases where corneal opacity is present. The method can be used in both primates and humans, making it applicable to a wide range of patients.
The medicament used in the method may also contain additional medicinal components, enhancing its therapeutic potential. In one embodiment, the medicament is in the form of eye drops, providing a convenient and non-invasive mode of administration.
Overall, this granted patent presents a method for treating Fuchs' endothelial corneal dystrophy and related conditions by inhibiting the TGF-beta signaling pathway. The method offers potential benefits for patients suffering from these eye disorders and may contribute to improved treatment options in the field of ophthalmology.
To know more about GlobalData’s detailed insights on Senju Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
